Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLAC Stock Forecast 2026-2027
$0.57
Current Price
$3.09M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BLAC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BLAC Price Momentum
+5.6%
1 Week Change
+29.5%
1 Month Change
-57.1%
1 Year Change
+1.8%
Year-to-Date Change
-68.2%
From 52W High of $1.79
+49.9%
From 52W Low of $0.38
📊 TOP ANALYST CALLS
Did BLAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bellevue Life Sciences is one of their latest high-conviction picks.
Latest BLAC Stock Price Targets & Analyst Predictions
BLAC has shown a year-to-date change of 1.8% and a 1-year change of -57.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BLAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLAC Analyst Ratings
0
Buy
0
Hold
0
Sell
BLAC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.57
Latest BLAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Bellevue Life Sciences Acquisition Corp. (BLAC) Competitors
The following stocks are similar to Bellevue Life Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BLAC
Bellevue Life Sciences
mkt cap
3.09M
Bellevue Life Sciences Acquisition Corp. (BLAC) Financial Data
Valuation Metrics
Market Cap
$3.09M
Enterprise Value
$0
P/E Ratio
540.5x
PEG Ratio
-0.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.5%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
+1.2%
ROA
+1.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bellevue Life Sciences Acquisition Corp. (BLAC) Business Model
About Bellevue Life Sciences Acquisition Corp.
What They Do
Facilitates investments in life sciences companies.
Business Model
The company operates as a special purpose acquisition company (SPAC), raising capital through its initial public offering to identify and merge with businesses in the life sciences sector. It targets industries such as biotechnology, pharmaceuticals, and medical devices, which are essential for healthcare advancements.
Additional Information
Bellevue Life Sciences Acquisition Corp. leverages its leadership's expertise to navigate public markets and promote strategic growth for its partner companies. By providing a streamlined path for life sciences firms to access public capital, it accelerates research, development, and commercialization in critical health-related fields.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Kuk Hyoun Hwang
Country
United States
IPO Year
2023
Website
www.bellevuespac.comBellevue Life Sciences Acquisition Corp. (BLAC) Latest News & Analysis
Latest News
Quick Summary
Bellevue Life Sciences Acquisition Corp. announced that stockholders approved all proposals, including the business combination with OSR Holdings Co., Ltd., at a special meeting on February 13, 2025.
Why It Matters
Approval of the business combination between BLAC and OSR Holdings signals potential growth opportunities, impacting stock performance and investor sentiment related to both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bellevue Life Sciences Acquisitions Corp. (BLAC) adjourned its special stockholder meeting on May 10, 2024, without conducting business and will reconvene on May 13, 2024, at 9:00 a.m.
Why It Matters
The adjournment of the special meeting without conducting business may signal uncertainty or issues within Bellevue Life Sciences, potentially affecting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
OSR Holdings has signed an MOU with SillaJen to collaborate on technology and clinical development for immuno-oncology drugs, aiming to create synergies in their respective platforms.
Why It Matters
OSR Holdings' collaboration with SillaJen may enhance drug development efficiency and innovation, potentially increasing both companies' market value and attractiveness to investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) is set to merge with OSR Holdings Co., Ltd., as announced on November 16, 2023. Further details on the deal were not provided.
Why It Matters
The announcement of a SPAC merger can affect stock volatility and investor sentiment, indicating potential growth opportunities or risks in the biotech sector linked to OSR Holdings.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bellevue Life Sciences Acquisition Corp. (BLAC) plans to merge with OSR Holdings, aiming for completion in Q4 2023, which would make OSR Holdings a publicly traded entity.
Why It Matters
The planned merger could lead to increased stock value for BLAC and provide investors access to OSR Holdings' potential growth in the healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BLAC Stock
What is Bellevue Life Sciences Acquisition Corp.'s (BLAC) stock forecast for 2026?
Analyst forecasts for Bellevue Life Sciences Acquisition Corp. (BLAC) are not currently available. The stock is trading at $0.57.
Is BLAC stock a good investment in 2026?
Analyst ratings for BLAC are not currently available. The stock is currently trading at $0.57. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLAC stock?
Price predictions from Wall Street analysts for BLAC are not currently available. The stock is trading at $0.57.
What is Bellevue Life Sciences Acquisition Corp.'s business model?
The company operates as a special purpose acquisition company (SPAC), raising capital through its initial public offering to identify and merge with businesses in the life sciences sector. It targets industries such as biotechnology, pharmaceuticals, and medical devices, which are essential for healthcare advancements.
What is the highest forecasted price for BLAC Bellevue Life Sciences Acquisition Corp.?
Price targets from Wall Street analysts for BLAC are not currently available. The stock is trading at $0.57.
What is the lowest forecasted price for BLAC Bellevue Life Sciences Acquisition Corp.?
Price targets from Wall Street analysts for BLAC are not currently available. The stock is trading at $0.57.
What is the overall BLAC consensus from analysts for Bellevue Life Sciences Acquisition Corp.?
Analyst ratings for BLAC are not currently available. The stock is trading at $0.57.
How accurate are BLAC stock price projections?
Stock price projections, including those for Bellevue Life Sciences Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:18 AM UTC